Differential regulation of myeloid leukemias by the bone marrow microenvironment

Nature Medicine

Volumn 19, Issue 11, 2013, Pages 1513-1517

  Krause, Daniela S ^a,b,c,d   Fulzele, Keertik ^d   Catic, André ^a,b,c   Sun, Chia Chi ^d   Dombkowski, David ^d   Hurley, Michael P ^a,b,c   Lezeau, Sanon ^a,b,c   Attar, Eyal ^d   Wu, Joy Y ^d   Lin, Herbert Y ^d   Divieti Pajevic, Paola ^d   Hasserjian, Robert P ^d   Schipani, Ernestina ^e   Van Etten, Richard A ^f   Scadden, David T ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b Harvard University   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; INTERLEUKIN 6; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW MICROENVIRONMENT; BONE REMODELING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; LOG RANK TEST; MICROENVIRONMENT; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BONE MARROW; FEMALE; GENES, ABL; HUMANS; LEUKEMIA, MYELOID; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; PARATHYROID HORMONE; SIGNAL TRANSDUCTION; STEM CELL NICHE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MICROENVIRONMENT;

MUS;

EID: 84887424411     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3364     Document Type: Article

References (25)

1. Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315-1321 (2007).
2. Krause, D.S. & Van Etten, R.A. Right on target: eradicating leukemic stem cells. Trends Mol. Med. 13, 470-481 (2007).
3. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. & Dick, J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174 (2006).
4. Krause, D.S., Lazarides, K., von Andrian, U.H. & Van Etten, R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12, 1175-1180 (2006).
5. Reynaud, D. et al. IL-6 controls leukemic mutipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661-673 (2011).
6. Tang, Y. et al. TGF-?1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009).
7. Naka, K. et al. TGF-?-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukemia. Nature 463, 676-680 (2010).
8. Calvi, L.M. et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107, 277-286 (2001).
9. Calvi, L.M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003).
10. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
11. Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
12. Li, S., Ilaria, R.L., Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399-1412 (1999).
13. Li, S. et al. Interleukin-3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97, 1442-1450 (2001).
14. Hu, Y. et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. USA 103, 16870-16875 (2006).
15. Gishizky, M.L. & Witte, O.N. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256, 836-839 (1992).
16. Ohishi, M. et al. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am. J. Pathol. 174, 2160-2171 (2009).
17. Wu, X. et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 7, 571-580 (2010).
18. Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovation in Leukemia Study Group. J. Clin. Oncol. 28, 2529-2537 (2010).
19. Radich, J.P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 103, 2794-2799 (2006).
20. Guo, J. et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 11, 161-171 (2010).
21. Heaney, N.B. et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 115, 2241-2250 (2010).
22. Wang, J.C.Y. et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91, 2406-2414 (1998).
23. Babitt, J.L. et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38, 531-539 (2006).
24. Burgess, T.L. et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538 (1999).
25. Somervaille, T.C.P. & Cleary, M.L. Identification and chracterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006)